586 related articles for article (PubMed ID: 15738535)
1. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU; Ibrahim NK; Francis D; Booser DJ; Thomas ES; Theriault RL; Pusztai L; Green MC; Arun BK; Giordano SH; Cristofanilli M; Frye DK; Smith TL; Hunt KK; Singletary SE; Sahin AA; Ewer MS; Buchholz TA; Berry D; Hortobagyi GN
J Clin Oncol; 2005 Jun; 23(16):3676-85. PubMed ID: 15738535
[TBL] [Abstract][Full Text] [Related]
2. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig G; Royce M; McCall LM; Ewer MS; Hunt KK;
Lancet Oncol; 2013 Dec; 14(13):1317-25. PubMed ID: 24239210
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
Zhang M; Li L; Zhang S; Zhu W; Yang S; Di G; Ma X; Yang H
Biomed Res Int; 2020; 2020():3208391. PubMed ID: 32461977
[TBL] [Abstract][Full Text] [Related]
4. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Esteva FJ; Wang J; Lin F; Mejia JA; Yan K; Altundag K; Valero V; Buzdar AU; Hortobagyi GN; Symmans WF; Pusztai L
Breast Cancer Res; 2007; 9(6):R87. PubMed ID: 18086299
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Perez EA; Suman VJ; Davidson NE; Sledge GW; Kaufman PA; Hudis CA; Martino S; Gralow JR; Dakhil SR; Ingle JN; Winer EP; Gelmon KA; Gersh BJ; Jaffe AS; Rodeheffer RJ
J Clin Oncol; 2008 Mar; 26(8):1231-8. PubMed ID: 18250349
[TBL] [Abstract][Full Text] [Related]
6. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).
Schneider BP; O'Neill A; Shen F; Sledge GW; Thor AD; Kahanic SP; Zander PJ; Davidson NE
Br J Cancer; 2015 Dec; 113(12):1651-7. PubMed ID: 26625004
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Albain KS; Yau C; Petricoin EF; Wolf DM; Lang JE; Chien AJ; Haddad T; Forero-Torres A; Wallace AM; Kaplan H; Pusztai L; Euhus D; Nanda R; Elias AD; Clark AS; Godellas C; Boughey JC; Isaacs C; Tripathy D; Lu J; Yung RL; Gallagher RI; Wulfkuhle JD; Brown-Swigart L; Krings G; Chen YY; Potter DA; Stringer-Reasor E; Blair S; Asare SM; Wilson A; Hirst GL; Singhrao R; Buxton M; Clennell JL; Sanil A; Berry S; Asare AL; Matthews JB; DeMichele AM; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Symmans WF; Van't Veer LJ; Yee D; Berry DA; Esserman LJ
Clin Cancer Res; 2024 Feb; 30(4):729-740. PubMed ID: 38109213
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Pusztai L; Yau C; Wolf DM; Han HS; Du L; Wallace AM; String-Reasor E; Boughey JC; Chien AJ; Elias AD; Beckwith H; Nanda R; Albain KS; Clark AS; Kemmer K; Kalinsky K; Isaacs C; Thomas A; Shatsky R; Helsten TL; Forero-Torres A; Liu MC; Brown-Swigart L; Petricoin EF; Wulfkuhle JD; Asare SM; Wilson A; Singhrao R; Sit L; Hirst GL; Berry S; Sanil A; Asare AL; Matthews JB; Perlmutter J; Melisko M; Rugo HS; Schwab RB; Symmans WF; Yee D; Van't Veer LJ; Hylton NM; DeMichele AM; Berry DA; Esserman LJ
Cancer Cell; 2021 Jul; 39(7):989-998.e5. PubMed ID: 34143979
[TBL] [Abstract][Full Text] [Related]
9. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Squifflet P; Saad ED; Loibl S; van Mackelenbergh MT; Untch M; Rastogi P; Gianni L; Schneeweiss A; Conte P; Piccart M; Bonnefoi H; Jackisch C; Nekljudova V; Tang G; Valagussa P; Neate C; Gelber R; Poncet C; Heinzmann D; Denkert C; Geyer CE; Cortes J; Guarneri V; de Azambuja E; Cameron D; Ismael G; Wolmark N; Cortazar P; Buyse M;
J Clin Oncol; 2023 Jun; 41(16):2988-2997. PubMed ID: 36977286
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.
Martin-Castillo B; Pernas S; Dorca J; Álvarez I; Martínez S; Pérez-Garcia JM; Batista-López N; Rodríguez-Sánchez CA; Amillano K; Domínguez S; Luque M; Stradella A; Morilla I; Viñas G; Cortés J; Cuyàs E; Verdura S; Fernández-Ochoa Á; Fernández-Arroyo S; Segura-Carretero A; Joven J; Pérez E; Bosch N; Garcia M; López-Bonet E; Saidani S; Buxó M; Menendez JA
Oncotarget; 2018 Nov; 9(86):35687-35704. PubMed ID: 30479698
[TBL] [Abstract][Full Text] [Related]
11. Retracted: Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.
International BR
Biomed Res Int; 2024; 2024():9785671. PubMed ID: 38549982
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Buzdar AU; Valero V; Ibrahim NK; Francis D; Broglio KR; Theriault RL; Pusztai L; Green MC; Singletary SE; Hunt KK; Sahin AA; Esteva F; Symmans WF; Ewer MS; Buchholz TA; Hortobagyi GN
Clin Cancer Res; 2007 Jan; 13(1):228-33. PubMed ID: 17200359
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Hegg R; Tausch C; Seo JH; Tsai YF; Ratnayake J; McNally V; Ross G; Cortés J
Ann Oncol; 2013 Sep; 24(9):2278-84. PubMed ID: 23704196
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Baselga J; Bradbury I; Eidtmann H; Di Cosimo S; de Azambuja E; Aura C; Gómez H; Dinh P; Fauria K; Van Dooren V; Aktan G; Goldhirsch A; Chang TW; Horváth Z; Coccia-Portugal M; Domont J; Tseng LM; Kunz G; Sohn JH; Semiglazov V; Lerzo G; Palacova M; Probachai V; Pusztai L; Untch M; Gelber RD; Piccart-Gebhart M;
Lancet; 2012 Feb; 379(9816):633-40. PubMed ID: 22257673
[TBL] [Abstract][Full Text] [Related]
19. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
20. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
